Checkpoint Therapeutics CKPT

$ 3.5 3.55%

Quarterly report 2024-Q3
added 11-12-2024

Checkpoint Therapeutics Balance Sheet 2011-2024 | CKPT

Annual Balance Sheet Checkpoint Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-40.8 M	-26.1 M	-22 M	-19.2 M	-35.1 M	-48 M	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	2.47 M	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	2.47 M	-	-	-	-
Total Current Liabilities	18.4 M	32.8 M	26 M	7.22 M	8.12 M	13.1 M	6.37 M	3.67 M	1.79 M	-	-	-	-
Total Liabilities	18.4 M	32.8 M	26 M	7.22 M	8.12 M	13.1 M	6.37 M	3.67 M	4.26 M	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-314 M	-262 M	-200 M	-143 M	-120 M	-95.4 M	-59 M	-36.4 M	-13.9 M	-	-	-	-
Total Assets	5.38 M	13.3 M	55.7 M	42.6 M	27 M	24.9 M	21.4 M	36 M	50.7 M	-	-	-	-
Cash and Cash Equivalents	4.93 M	12.1 M	54.7 M	40.8 M	26.1 M	22 M	19.2 M	35.1 M	50.4 M	-	-	-	-
Book Value	-13 M	-19.5 M	29.7 M	35.4 M	18.8 M	11.8 M	15 M	32.3 M	46.4 M	-	-	-	-
Total Shareholders Equity	-13 M	-19.5 M	29.7 M	35.4 M	18.8 M	11.8 M	15 M	32.3 M	46.4 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Checkpoint Therapeutics

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	17.8 M	21.4 M	18.4 M	21.3 M	31.6 M	28.1 M	32.8 M	23 M	24.6 M	22.7 M	26 M	13 M	9.25 M	7.26 M	7.22 M	7.22 M	7.22 M	7.22 M	8.12 M	8.12 M	8.12 M	8.12 M	13.1 M	13.1 M	13.1 M	13.1 M	6.37 M	6.37 M	6.37 M	6.37 M	3.67 M	3.67 M	3.67 M	3.67 M	4.26 M	4.26 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-342 M	-332 M	-314 M	-295 M	-289 M	-273 M	-262 M	-241 M	-231 M	-217 M	-200 M	-170 M	-159 M	-150 M	-143 M	-143 M	-143 M	-143 M	-120 M	-120 M	-120 M	-120 M	-95.4 M	-95.4 M	-95.4 M	-95.4 M	-59 M	-59 M	-59 M	-59 M	-36.4 M	-36.4 M	-36.4 M	-36.4 M	-13.9 M	-13.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	5.18 M	5.67 M	5.38 M	2.22 M	8.34 M	5.9 M	13.3 M	21.6 M	32.1 M	42.9 M	55.7 M	61 M	66.1 M	61.4 M	42.6 M	42.6 M	42.6 M	42.6 M	27 M	27 M	27 M	27 M	24.9 M	24.9 M	24.9 M	24.9 M	21.4 M	21.4 M	21.4 M	21.4 M	36 M	36 M	36 M	36 M	50.7 M	50.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	4.7 M	4.95 M	4.93 M	1.77 M	7.42 M	4.85 M	12.1 M	20.5 M	30.9 M	41.5 M	54.7 M	60.2 M	65.1 M	60 M	40.8 M	40.8 M	40.8 M	40.8 M	26.1 M	26.1 M	26.1 M	26.1 M	22 M	22 M	22 M	22 M	19.2 M	19.2 M	19.2 M	19.2 M	35.1 M	35.1 M	35.1 M	35.1 M	50.4 M	50.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-12.6 M	-15.7 M	-13 M	-19 M	-23.3 M	-22.2 M	-19.5 M	-1.34 M	7.46 M	20.2 M	29.7 M	48 M	56.9 M	54.2 M	35.4 M	35.4 M	35.4 M	35.4 M	18.8 M	18.8 M	18.8 M	18.8 M	11.8 M	11.8 M	11.8 M	11.8 M	15 M	15 M	15 M	15 M	32.3 M	32.3 M	32.3 M	32.3 M	46.4 M	46.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-12.6 M	-15.7 M	-13 M	-19 M	-23.3 M	-22.2 M	-19.5 M	-1.34 M	7.46 M	20.2 M	29.7 M	48 M	56.9 M	54.2 M	35.4 M	35.4 M	35.4 M	35.4 M	18.8 M	18.8 M	18.8 M	18.8 M	11.8 M	11.8 M	11.8 M	11.8 M	15 M	15 M	15 M	15 M	32.3 M	32.3 M	32.3 M	32.3 M	46.4 M	46.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency